A phase 1/2 trial of AK109+AK104 in advanced solid tumours, run by Akeso, now recruiting.
A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05142423 by Akeso, with 198 participants planned, started 2021-11-03 and due to reach its primary completion in 2027-04. Interventions recorded: AK109+AK104.
Shares Akeso, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Akeso, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Akeso and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.